I am a physician assistant in Internal Medicine writing in opposition to the plan to change approval criteria for Wegovy weight loss medication. Treating obesity is not always about the weight loss, although that is usually what excites patients the most. Treating obesity is about managing and preventing chronic disease early on, which improves quality of life. I have only experienced great results with this medication in practice, that is for patients who are lucky enough to receive it after jumping through various "hoops" with insurance coverage and pharmacies. These patients are often very exhausted after years of trying alternative lifestyle modifications, diets, exercise programs and nutritionist consults. The debilitating chronic diseases that result from obesity need to prevented and treated as best as possible, and GLP-1 agonists are very promising for this reason. Patients and providers do not need more barriers to access these medications.